Search

Your search keyword '"Besse, B."' showing total 2,147 results
Start Over Author "Besse, B."
2,147 results on '"Besse, B."'

2. Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating EGFR Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus Survey.

Author

Ou SI, Le X, Nagasaka M, Reungwetwattana T, Ahn MJ, Lim DW, Santos ES, Shum E, Lau SC, Lee JB, Calles A, Wu F, Lopes G, Sriuranpong V, Tanizaki J, Horinouchi H, Garassino MC, Popat S, Besse B, Rosell R, and Soo RA

Subjects
egfr mutations, expert panel, top 20 papers, 20th anniversary, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Sai-Hong Ignatius Ou,1 Xiuning Le,2 Misako Nagasaka,1 Thanyanan Reungwetwattana,3 Myung-Ju Ahn,4 Darren WT Lim,5 Edgardo S Santos,6 Elaine Shum,7 Sally CM Lau,7 Jii Bum Lee,8 Antonio Calles,9 Fengying Wu,10 Gilberto Lopes,11 Virote Sriuranpong,12 Junko Tanizaki,13 Hidehito Horinouchi,14 Marina C Garassino,15 Sanjay Popat,16 Benjamin Besse,17 Rafael Rosell,18 Ross A Soo19 1University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange, CA, USA; 2University of Texas MD Anderson Cancer Center, Houston, TX, USA; 3Division of Medical Oncology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; 4Department of Hematology and Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; 5Duke-NUS School of medicine, National Cancer Center Singapore, Republic of Singapore; 6Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL, 33431, USA; 7NYU Langone Perlmutter Cancer Center, NY, NY, USA; 8Yonsei Cancer Center Yonsei University, Seoul, Republic of Korea; 9Department of Medicine, Division of Medical Oncology, Early Drug Development and Phase I Unit, Hospital General Universitario Gregorio Marañón, Madrid, 28007, Spain; 10Shanghai Chest hospital, Tongji University School of Medicine, Shanghai, People’s Republic of China; 11Department of Medicine, Division of Medical Oncology, Sylvester Comprehensive Cancer Center at the University of Miami and the Miller School of Medicine, Miami, FL, 33136, USA; 12Chulalongkorn University, King Chulalongkorn Memorial Hospital, Bangkok, Thailand; 13Department of Medicine, Kindai University School of Medicine, Osaka, Japan; 14Department of Thoracic Oncology, National Cancer Center Hospital Tokyo, Tokyo, Japan; 15Department of Medicine, Division of Medical Oncology-Hematology, University of Chicago Medicine, Chicago, IL, USA; 16Royal Marsden Hospital, London, Imperial College, London, UK; 17Gustave Roussy Cancer Campus, Villejuif, France; Paris-Saclay University, Orsay, France; 18Department of Hematology-Oncology, National University Cancer Institute, National University Hospital Singapore, Republic of Singapore; 19IOR, Quirón-Dexeus University Institute; ICO, Catalan Institute of Oncology; IGTP, Germans Trias i Pujol Research Institute, Barcelona, SpainCorrespondence: Sai-Hong Ignatius Ou, University of California School of Medicine, Department of Medicine, Division of Hematology-Oncology, Chao Family Comprehensive Cancer Center, 200 South Manchester Avenue, Suite 400, Orange, CA, 92868, USA, Tel +1 714-456-5153, Fax +1 714-456-2242, Email Siou@hs.uci.eduAbstract: The year 2024 is the 20th anniversary of the discovery of activating epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC). Since then, tremendous advances have been made in the treatment of NSCLC based on this discovery. Some of these studies have led to seismic changes in the concept of oncology research and spurred treatment advances beyond NSCLC, leading to a current true era of precision oncology for all solid tumors. We now routinely molecularly profile all tumor types and even plasma samples of patients with NSCLC for multiple actionable driver mutations, independent of patient clinical characteristics nor is profiling limited to the advanced incurable stage. We are increasingly monitoring treatment responses and detecting resistance to targeted therapy by using plasma genotyping. Furthermore, we are now profiling early-stage NSCLC for appropriate adjuvant targeted treatment leading to an eventual potential “cure” in early-stage EGFR+ NSCLC which have societal implication on implementing lung cancer screening in never-smokers as most EGFR+ NSCLC patients are never-smokers. All these advances were unfathomable in 2004 when the five papers that described “discoveries” of activating EGFR mutations (del19, L858R, exon 20 insertions, and “uncommon” mutations) were published. To commemorate this 20th anniversary, we assembled a global panel of thoracic medical oncology experts to select the top 20 papers (publications or congress presentation) from the 20 years since this seminal discovery with December 31, 2023 as the cutoff date for inclusion of papers to be voted on. Papers ranked 21 to 30 were considered “honorable mention” and also annotated. Our objective is that these 30 papers with their annotations about their impact and even all the ranked papers will serve as “syllabus” for the education of future thoracic oncology trainees. Finally, we mentioned potential practice-changing clinical trials to be reported. One of them, LAURA was published online on June 2, 2024 was not included in the list of papers to be voted on but will surely be highly ranked if this consensus survery is performed again on the 25th anniversay of the discovery EGFR mutations (i.e. top 25 papers on the 25 years since the discovery of activating EGFR mutations).Keywords: EGFR mutations, expert panel, top 20 papers, 20th anniversary, NSCLC

Published
2024

3. Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA

Author

Felip, E., Cho, B.C., Gutiérrez, V., Alip, A., Besse, B., Lu, S., Spira, A.I., Girard, N., Califano, R., Gadgeel, S.M., Yang, J.C.-H., Yamamoto, S., Azuma, K., Kim, Y.J., Lee, K.-H., Danchaivijitr, P., Ferreira, C.G., Cheng, Y., Sendur, M.A.N., Chang, G.-C., Wang, C.-C., Prabhash, K., Shinno, Y., Stroyakovskiy, D., Paz-Ares, L., Rodriguez-Cid, J.R., Martin, C., Campelo, M.R.G., Hayashi, H., Nguyen, D., Tomasini, P., Gottfried, M., Dooms, C., Passaro, A., Schuler, M., Gelatti, A.C.Z., Owen, S., Perdrizet, K., Ou, S.-H.I., Curtin, J.C., Zhang, J., Gormley, M., Sun, T., Panchal, A., Ennis, M., Fennema, E., Daksh, M., Sethi, S., Bauml, J.M., and Lee, S.-H.

Published
2024
Full Text
View/download PDF

4. Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1

Author

Zemanová, M., Besse, B., Bonnet, C., Cadranel, J., Chouaid, C., Cortot, A., Debieuvre, D., Delclaux, B., Denis, F., Duchemann, B., El Kouri, C., Ferrand, F.R., Ginoux, M., Hilgers, W., Madroszyk, A., Masson, P., Mazieres, J., Molinier, O., Moro-Sibilot, D., Pichon, E., Mascaux, C., Robinet, G., Roch, B., Zalcman, G., Schmidtke-Schrezenmeier, G., Schuette, W., Urban, L., Gottfried, M., Nechushtan, H., Peled, N., Wollner, M., Zer, A., Baldini, E., Bonanno, L., Bonetti, A., Cappuzzo, F., Delmonte, A., Galetta, D., Maio, M., Minotti, V., Rea, A., Romano, G., Tassinari, D., Tonini, G., Dziadziuszko, R., Karaszewska, B., Szczęsna, A., Cobo, M., De Castro, J., Felip, E., Garcia Campelo, M.R., Hernández, A., Moran, T., Provencio, M., Viteri, S., Dasgupta, A., Gabrail, N., Giaccone, G., Harshad, A., Liu, S., Oubre, D., Panikkar, R., Razaq, M., Sanborn, R., Garcia Campelo, R., Remon, J., Costantini, D., and Vasseur, B.

Published
2023
Full Text
View/download PDF

8. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

Author

Mazieres, J, Drilon, A, Lusque, A, Mhanna, L, Cortot, AB, Mezquita, L, Thai, AA, Mascaux, C, Couraud, S, Veillon, R, Van den Heuvel, M, Neal, J, Peled, N, Früh, M, Ng, TL, Gounant, V, Popat, S, Diebold, J, Sabari, J, Zhu, VW, Rothschild, SI, Bironzo, P, Martinez-Marti, A, Curioni-Fontecedro, A, Rosell, R, Lattuca-Truc, M, Wiesweg, M, Besse, B, Solomon, B, Barlesi, F, Schouten, RD, Wakelee, H, Camidge, DR, Zalcman, G, Novello, S, Ou, SI, Milia, J, and Gautschi, O

Subjects
Lung, Cancer, Clinical Research, Clinical Trials and Supportive Activities, Lung Cancer, Development of treatments and therapeutic interventions, 5.1 Pharmaceuticals, Good Health and Well Being, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Immunological, Antineoplastic Combined Chemotherapy Protocols, B7-H1 Antigen, Biomarkers, Tumor, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Oncogenes, Programmed Cell Death 1 Receptor, Progression-Free Survival, Registries, Response Evaluation Criteria in Solid Tumors, Retrospective Studies, immunotherapy, lung cancer, oncogenic addiction, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

BackgroundAnti-PD1/PD-L1 directed immune checkpoint inhibitors (ICI) are widely used to treat patients with advanced non-small-cell lung cancer (NSCLC). The activity of ICI across NSCLC harboring oncogenic alterations is poorly characterized. The aim of our study was to address the efficacy of ICI in the context of oncogenic addiction.Patients and methodsWe conducted a retrospective study for patients receiving ICI monotherapy for advanced NSCLC with at least one oncogenic driver alteration. Anonymized data were evaluated for clinicopathologic characteristics and outcomes for ICI therapy: best response (RECIST 1.1), progression-free survival (PFS), and overall survival (OS) from ICI initiation. The primary end point was PFS under ICI. Secondary end points were best response (RECIST 1.1) and OS from ICI initiation.ResultsWe studied 551 patients treated in 24 centers from 10 countries. The molecular alterations involved KRAS (n = 271), EGFR (n = 125), BRAF (n = 43), MET (n = 36), HER2 (n = 29), ALK (n = 23), RET (n = 16), ROS1 (n = 7), and multiple drivers (n = 1). Median age was 60 years, gender ratio was 1 : 1, never/former/current smokers were 28%/51%/21%, respectively, and the majority of tumors were adenocarcinoma. The objective response rate by driver alteration was: KRAS = 26%, BRAF = 24%, ROS1 = 17%, MET = 16%, EGFR = 12%, HER2 = 7%, RET = 6%, and ALK = 0%. In the entire cohort, median PFS was 2.8 months, OS 13.3 months, and the best response rate 19%. In a subgroup analysis, median PFS (in months) was 2.1 for EGFR, 3.2 for KRAS, 2.5 for ALK, 3.1 for BRAF, 2.5 for HER2, 2.1 for RET, and 3.4 for MET. In certain subgroups, PFS was positively associated with PD-L1 expression (KRAS, EGFR) and with smoking status (BRAF, HER2).Conclusions: ICI induced regression in some tumors with actionable driver alterations, but clinical activity was lower compared with the KRAS group and the lack of response in the ALK group was notable. Patients with actionable tumor alterations should receive targeted therapies and chemotherapy before considering immunotherapy as a single agent.

Published
2019

14. 147O Scope of NUT carcinomas (NC): An international multicentric study

Author

Becerra, M.V. Sanchez, primary, Knetki-Wroblewska, M., additional, O'Reilly, S., additional, Larroya, M. Bover, additional, Montañez, J.C. Benitez, additional, Martorell, P. Martin, additional, Contreras, S. Sandiego, additional, Ghigna, M.R., additional, Markellos, C., additional, Burgy, M., additional, Hulo, P., additional, Mangon, Q., additional, Guerrero, R. Motta, additional, Chapron, J., additional, Lavaud, P., additional, Massard, C.P., additional, Even, C., additional, Cozic, N., additional, Fresneau, B., additional, and Besse, B., additional

Published
2024
Full Text
View/download PDF

18. Les tumeurs thymiques : principes de prise en charge

Author

Agrafiotis, A., Arrondeau, J., Besse, B., and Girard, N.

Abstract

Les tumeurs épithéliales thymiques sont des tumeurs rares, d’évolution et de pronostic variable. La classification histopathologique distingue deux principaux types tumoraux : les thymomes, qui reproduisent l’architecture du thymus normal, associant des cellules épithéliales thymiques tumorales et des lymphocytes non tumoraux, et les carcinomes thymiques. Des manifestations auto-immunes sont mises en évidence chez près d’un tiers des patients au diagnostic; la myasthénie est la plus fréquente, avec l’érythroblastopénie et l’hypogammaglobulinémie. Le système de stadification historique est celui de Masaoka, revu par Koga; le système TNM est standard depuis 2018.

Published
2024
Full Text
View/download PDF

21. Meningeal “Lazarus Response” to Lorlatinib in a ROS1-Positive NSCLC Patient Progressing to Entrectinib

Author

Facchinetti F, Levy A, Ammari S, Naltet C, Lavaud P, Aldea M, Vasseur D, Planchard D, and Besse B

Subjects
tyrosine kinase inhibitors (tki), central nervous system (cns), brain, lung cancer, radiotherapy., Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Francesco Facchinetti,1,2 Antonin Levy,3,4 Samy Ammari,5 Charles Naltet,6 Pernelle Lavaud,6 Mihaela Aldea,6 Damien Vasseur,7 David Planchard,6 Benjamin Besse2,6 1Predictive Biomarkers and Novel Therapeutic Strategies in Oncology, Inserm U981, Gustave Roussy Cancer Center, Villejuif, France; 2Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France; 3Department of Radiation Oncology, Institut d’Oncologie Thoracique (IOT), Gustave Roussy Cancer Center, Villejuif, France; 4INSERM U1030, Molecular Radiotherapy, Gustave Roussy, Université Paris-Saclay, Villejuif, France; 5Department of Radiology, Gustave Roussy Cancer Center, Villejuif, France; 6Department of Medical Oncology, Institut d’Oncologie Thoracique (IOT), Gustave Roussy Cancer Center, Villejuif, France; 7Department of Medical Biology and Pathology, Gustave Roussy Cancer Center, Villejuif, FranceCorrespondence: Benjamin BesseDepartment of Medical Oncology, Institut d’Oncologie Thoracique (IOT), Gustave Roussy Cancer Center, Villejuif, FranceEmail benjamin.besse@gustaveroussy.frBackground: ROS1 tyrosine kinase inhibitors (TKIs) have showed activity and efficacy in ROS1-rearranged non-small cell lung cancer (NSCLC). In the clinical practice, besides the utilization of crizotinib, less is known about the best treatment strategies involving additional, new-generation TKIs for the sequential treatment of ROS1-positive NSCLC patients.Case Presentation: A patient suffering from a ROS1-rearranged lung adenocarcinoma, after receiving cisplatin-pemetrexed chemotherapy, was treated with entrectinib, a new-generation ALK/ROS1/NTRK inhibitor. After 16 months, central nervous system (CNS) metastases appeared, without extra-cerebral disease progression. Stereotactic brain radiotherapy was performed and entrectinib was maintained, due to the global systemic disease control. Approximately one month after radiotherapy, thoracic and meningeal progressions were detected, the latter highly symptomatic with neurocognitive disorders, visual hallucinations and worsening of psycho-motor impairment. A lumbar puncture was positive for tumor cells and for an EZR-ROS1 fusion. The administration of lorlatinib (a third-generation ALK/ROS1 inhibitor) prompted an extremely rapid improvement of clinical conditions, anticipating the positive results observed at radiologic evaluation that confirmed the disease response still ongoing after nine months since treatment start.Discussion: With the expanding availability of targeted agents with differential activity on resistance mechanism and on CNS disease, choosing wisely the best treatment strategies is pivotal to assure the best clinical outcomes in oncogene-addicted NSCLC patients. Here we have reported lorlatinib reverted an almost fatal meningeal carcinomatosis developing during entrectinib in a ROS1-positive NSCLC patient.Keywords: tyrosine kinase inhibitors, TKI, central nervous system, CNS, brain, lung cancer, radiotherapy

Published
2021

26. Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1

Author

Besse, B., primary, Felip, E., additional, Garcia Campelo, R., additional, Cobo, M., additional, Mascaux, C., additional, Madroszyk, A., additional, Cappuzzo, F., additional, Hilgers, W., additional, Romano, G., additional, Denis, F., additional, Viteri, S., additional, Debieuvre, D., additional, Galetta, D., additional, Baldini, E., additional, Razaq, M., additional, Robinet, G., additional, Maio, M., additional, Delmonte, A., additional, Roch, B., additional, Masson, P., additional, Schuette, W., additional, Zer, A., additional, Remon, J., additional, Costantini, D., additional, Vasseur, B., additional, Dziadziuszko, R., additional, Giaccone, G., additional, Zemanová, M., additional, Besse, B., additional, Bonnet, C., additional, Cadranel, J., additional, Chouaid, C., additional, Cortot, A., additional, Delclaux, B., additional, Duchemann, B., additional, El Kouri, C., additional, Ferrand, F.R., additional, Ginoux, M., additional, Mazieres, J., additional, Molinier, O., additional, Moro-Sibilot, D., additional, Pichon, E., additional, Zalcman, G., additional, Schmidtke-Schrezenmeier, G., additional, Urban, L., additional, Gottfried, M., additional, Nechushtan, H., additional, Peled, N., additional, Wollner, M., additional, Bonanno, L., additional, Bonetti, A., additional, Minotti, V., additional, Rea, A., additional, Tassinari, D., additional, Tonini, G., additional, Karaszewska, B., additional, Szczęsna, A., additional, De Castro, J., additional, Garcia Campelo, M.R., additional, Hernández, A., additional, Moran, T., additional, Provencio, M., additional, Dasgupta, A., additional, Gabrail, N., additional, Harshad, A., additional, Liu, S., additional, Oubre, D., additional, Panikkar, R., additional, and Sanborn, R., additional

Published
2023
Full Text
View/download PDF

27. 1P Integrated data analysis within IMMUcan identifies prognostic features of early NSCLC

Author

Schulz, D., primary, Morfouace, M., additional, Eling, N., additional, Daniel, M., additional, Déglise, S., additional, Fernandez, B. Palau, additional, Windhager, J., additional, Rusakiewicz, S., additional, Tissot, S., additional, Trefzer, T., additional, Merlevede, J., additional, Marzetta, F., additional, Liechti, R., additional, Hong, H.S., additional, Cufer, T., additional, Bironzo, P., additional, Dingemans, A-M.C., additional, Besse, B., additional, and Bodenmiller, B., additional

Published
2023
Full Text
View/download PDF

28. 120MO Adjuvant pembrolizumab versus placebo for early-stage NSCLC after resection and optional chemotherapy: Updated results from PEARLS/KEYNOTE-091

Author

Besse, B., primary, Havel, L., additional, Peters, S., additional, Marreaud, S.I., additional, Jha, N., additional, Oselin, K., additional, Esteban Gonzalez, E., additional, Isla Casado, M.D., additional, Martinez-Marti, A., additional, Faehling, M., additional, Lee, J-S., additional, Luo, Y., additional, Keller, S.M., additional, Dafni, U., additional, Mauer, M.E., additional, Stahel, R.A., additional, O'Brien, M.E.R., additional, Tsuboi, M., additional, and Paz-Ares, L., additional

Published
2023
Full Text
View/download PDF

30. PCR181 Health-Related Quality-of-Life of Patients Treated with Repotrectinib for Neurotrophic Tyrosine Receptor Kinase (NTRK)-Positive Advanced Solid Tumors: Results from TRIDENT-1

Author

Sherif, B., primary, Besse, B., additional, Solomon, B., additional, Bazhenova, L., additional, Kim, D.W., additional, Lin, J.J., additional, Wolf, J., additional, Popat, S., additional, Goto, K., additional, de Langen, A.J., additional, Springfeld, C., additional, Reynolds, M., additional, Odom, D., additional, Yuan, Y., additional, Lee, A., additional, Blum, S.I., additional, Thamake, S., additional, Ades, F., additional, and Drilon, A., additional

Published
2023
Full Text
View/download PDF

32. OA06.03 An International EORTC Survey on Resectability of Stage III Non-small Cell Lung Cancer

Author

Houda, I., primary, Bahce, I., additional, Dickhoff, C., additional, Kroese, T.E., additional, Kroeze, S.G.C., additional, Mariolo, A.V., additional, Tagliamento, M., additional, Moliner, L., additional, Brandao, M., additional, Edwards, J., additional, Opitz, I., additional, Faivre-Finn, C., additional, de Ruysscher, D., additional, Remon, J., additional, Berghmans, T., additional, Dingemans, A.-M.C., additional, Besse, B., additional, and Hendriks, L.E.L., additional

Published
2023
Full Text
View/download PDF

33. MA08.04 Assessment of the Quality of the Surgical Procedure and the Operative Report Based on Nationwide French Registry: A RYTHMIC study

Author

Benítez, J.C., primary, Florez-Arango, J.D., additional, Boucher, M.-E., additional, Belaroussis, Y., additional, Jougon, J., additional, Hustache-Castaing, R., additional, Brouchet, L., additional, CAZAUX, M., additional, Gossot, D., additional, Boddaert, G., additional, Sage, E., additional, Glorion, M., additional, Mercier, O., additional, Menager, J.-B., additional, Falcoz, P.-E., additional, Pages, P.-B., additional, Madeleine, L., additional, Delatour, B., additional, Mauduit, M., additional, Fournel, L., additional, Prieto, M., additional, Missy, P., additional, Tran, Q., additional, Thomas, P., additional, Girard, N., additional, Besse, B., additional, and Brioude, G., additional

Published
2023
Full Text
View/download PDF

34. MA14.08 Pathogenic Germline Variants in Patients with Non-Small Cell Lung Cancer (NSCLC) Detected by Tissue Comprehensive Genomic Profiling

Author

Mezquita, L., primary, Kuang, Z., additional, Sivakumar, S., additional, Sokol, E.S., additional, Laguna, J.C., additional, Pastor, B., additional, Nalda, I., additional, Turrisi, F., additional, Aguilar, L., additional, Arcocha, A., additional, Potrony, M., additional, Solé, X., additional, Teixido, C., additional, Prat, A., additional, and Besse, B., additional

Published
2023
Full Text
View/download PDF

35. OA03.06 Repotrectinib in Patients with ROS1 Fusion-positive (ROS1+) NSCLC: Update from the Pivotal Phase 1/2 TRIDENT-1 Trial

Author

Cho, B.C., primary, Camidge, D.R., additional, Lin, J.J., additional, Kim, S.-W., additional, Solomon, B., additional, Dziadziuszko, R., additional, Besse, B., additional, Goto, K., additional, de Langen, A.J., additional, Wolf, J., additional, Lee, K.H., additional, Popat, S., additional, Springfeld, C., additional, Nagasaka, M., additional, Felip, E., additional, Yang, N., additional, Lu, S., additional, Kao, S., additional, Velcheti, V., additional, Cheema, P., additional, Stopatschinskaja, S., additional, Mehta, M., additional, Trone, D., additional, Ades, F., additional, Calvet, C.Y., additional, and Drilon, A., additional

Published
2023
Full Text
View/download PDF

36. P1.18-03 Patients with Smoking-Associated Atherosclerotic Cardiovascular Diseases: Does Prevalung Refines Eligibility for Screening?

Author

Boulate, D., primary, Fidelle, M., additional, Caramella, C., additional, Issard, J., additional, Planché, O., additional, Pradère, P., additional, Dauriat, G., additional, Garelik, D., additional, Mussot, S., additional, Mitilian, D., additional, Hache, O., additional, Lamrani, L., additional, Zins, M., additional, Beaussier, H., additional, Chatellier, G., additional, Fadel, E., additional, Zitvogel, L., additional, Besse, B., additional, and Mercier, O., additional

Published
2023
Full Text
View/download PDF

37. OA15.05 Lung Immune Prognostic Index Predicts Outcomes from Upfront Chemotherapy + Immunotherapy +/- Antiangiogenic in Advanced NSCLC

Author

Roulleaux Dugage, M., primary, Gorria, T., additional, Rochand, A., additional, Garcin, L.-M., additional, Oudard, S., additional, Albarrán-Artahona, V., additional, Laguna, J.C., additional, Nalda, I., additional, Muñoz-Carrillo, F.J., additional, Aguilar, L., additional, Arcocha, A., additional, Lupinacci, L., additional, Teixidó, C., additional, Besse, B., additional, Mezquita, L., additional, and Auclin, E., additional

Published
2023
Full Text
View/download PDF

39. EP13.07-06 Efficacy of Platinum Given after Lurbinectedin in Sensitive Relapsed SCLC Patients

Author

Trigo, J.M., primary, Besse, B., additional, Zaman, K., additional, Sala, M.Á., additional, Moreno, V., additional, López, R., additional, Lopez-Vilariño, J.A., additional, Fernandez, C., additional, Nieto, A., additional, Kahatt, C., additional, Zeaiter, A., additional, Antón, A., additional, Valdivia, J., additional, Wanesson, L., additional, and Subbiah, V., additional

Published
2023
Full Text
View/download PDF

40. P2.09-29 Efficacy of Osimertinib (OSI) vs 1st-Generation TKI Followed by OSI by Clinical Profile in EGFR-Mutant NSCLC (SMILE STUDY)

Author

Auclin, E., primary, Du Rusquec, P., additional, Albarran, V., additional, Aboubakar, F., additional, Gerber, H., additional, Epaillard, N., additional, Recondo, G., additional, De Giglio, A., additional, Berthou, H., additional, Fabre, E., additional, Laguna, J.C., additional, Blaquier, J.-B., additional, Jimenez-Munarriz, B., additional, Tagliamento, M., additional, Di Federico, A., additional, Sacco, G., additional, Minatta, J., additional, Girard, N., additional, Moran-Bueno, T., additional, Lopez-Castro, R., additional, Besse, B., additional, and Mezquita, L., additional

Published
2023
Full Text
View/download PDF

41. P1.23-07 Clinical Impact of Clonal Hematopoiesis in Patients with Advanced Non-small Cell Lung Cancer: Results of the CHIC Study

Author

Tagliamento, M., primary, Marzac, C., additional, Aldea, M., additional, Vasseur, D., additional, Bayle, A., additional, Gazzah, A., additional, Ngocamus, M., additional, Nicotra, C., additional, Levy, A., additional, Baldini, C., additional, Blanc-Durand, F., additional, Rouleau, E., additional, Italiano, A., additional, Lacroix, L., additional, Friboulet, L., additional, Planchard, D., additional, Barlesi, F., additional, Loriot, Y., additional, Micol, J.-B., additional, and Besse, B., additional

Published
2023
Full Text
View/download PDF

42. P2.07-05 Immune Checkpoint Blockers in Lung Cancer after Solid Organ Transplantation: INNOVATED Registry

Author

Remon Masip, J., primary, Auclin, E., additional, Aboubakar Nana, F., additional, Schneider, S., additional, Gautschi, O., additional, Zubiri, L., additional, Pierret, T., additional, Rodriguez-Abreu, D., additional, Blais, N., additional, Aldea, M., additional, Barlesi, F., additional, Planchard, D., additional, and Besse, B., additional

Published
2023
Full Text
View/download PDF

43. P1.22-19 Determination of the Membranous Expression of cMET in Patients with Advanced NSCLC and RET Fusions

Author

Marinello, A., primary, Ghigna, M.R., additional, Mandarano, M., additional, Russo, A., additional, Gazzah, A., additional, Godefroy, K., additional, Vasseur, D., additional, Cotteret, S., additional, Remon, J., additional, Barlesi, F., additional, Planchard, D., additional, Metro, G., additional, Scoazec, J.-Y., additional, Besse, B., additional, and Aldea, M., additional

Published
2023
Full Text
View/download PDF

44. P1.22-20 High Incidence of Ischemic Stroke in Patients with Non-small cell lung cancer and RET fusions

Author

Aldea, M., primary, Marinello, A., additional, Guyon, D., additional, Gazzah, A., additional, Bihoreau, J., additional, Smaali, S., additional, Danlos, F.X., additional, Laparra, A., additional, Ciuffini, L.A., additional, Grecea, M., additional, Abdayem, P., additional, Frelaut, M., additional, Lavaud, P., additional, Remon Masip, J., additional, Barlesi, F., additional, Planchard, D., additional, and Besse, B., additional

Published
2023
Full Text
View/download PDF

45. 80P Tumor microenvironment (TME) defines prognosis of EGFR-mutant non-small cell lung cancer (NSCLC)

Author

Zullo, L., primary, Ghigna, M.R., additional, Zrafi, W.S., additional, Marinello, A., additional, Vasseur, D., additional, Frelaut, M., additional, Abdayem, P., additional, Tagliamento, M., additional, Lavaud, P., additional, Gazzah, A., additional, Friboulet, L., additional, Scoazec, J-Y., additional, Remon, J., additional, Barlesi, F., additional, Besse, B., additional, Planchard, D., additional, and Aldea, M., additional

Published
2023
Full Text
View/download PDF

47. The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRASG12D-driven non-small cell lung cancer

Author

McDaid, W. J., primary, Wilson, L., additional, Adderley, H., additional, Baker, M. J., additional, Searle, J., additional, Ginn, L., additional, Budden, T., additional, Aldea, M., additional, Marinello, A., additional, Aredo, J., additional, Viros, A., additional, Besse, B., additional, Wakelee, H. A., additional, Blackhall, F., additional, Lindsay, C. R., additional, and Malliri, A., additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results